

The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

On January 12, 2026, Teva Pharmaceuticals USA, Inc. (Teva USA) initiated a recall of *the below six (6) lots* of **Isotretinoin Capsules USP, 30 mg and 40 mg** to the WHOLESAL LEVEL. **This UPDATE is to inform you that the scope of the recall was updated from the WHOLESAL LEVEL to the RETAIL LEVEL.** The products in this recall were distributed under the Teva Pharmaceuticals USA Inc. label. The reason the six (6) lots listed in the table below are being recalled is the possibility that some of the capsules in these lots may have an Isotretinon assay outside the specified range of "90.0% to 110.0%". As a result, the frequency and intensity of adverse reactions may be higher with exposure to capsules having an Isotretinoin assay above the specification range, and with exposure to capsules having an assay below the specification range, there is a risk of underdose which may result in lack of efficacy or decreased efficacy. Teva's health hazard assessment concluded that exposure to the product of concern could lead to moderate adverse events, and the likelihood of harm occurrence is remote. Consequently, the overall risk of harm in patient population is considered to be low.

This recall is being made with the knowledge of the Food and Drug Administration.

Isotretinoin Capsules USP, 30 mg and 40 mg

Lot	Exp. Date	Strength	Size	NDC Carton	NDC Blister Pack
1000S5426	02/2026				
100071518	04/2027	30mg	30 capsules	0591-2435-15	0591-2435-45
100072450	07/2027				
100075305	06/2027				
100075512	07/2027	40mg	30 capsules	0591-2436-15	0591-2436-45
100076103	07/2027				